CL2012001485A1 - Compuestos derivados de benzofurano, benzooxazol y benzo[d]oxadol, como inhibidores de mek; composicion farmaceutica que los comprende, utiles en el tratamiento de enfermedades hiperproliferativas, tales como cancer e inflamacion. - Google Patents
Compuestos derivados de benzofurano, benzooxazol y benzo[d]oxadol, como inhibidores de mek; composicion farmaceutica que los comprende, utiles en el tratamiento de enfermedades hiperproliferativas, tales como cancer e inflamacion.Info
- Publication number
- CL2012001485A1 CL2012001485A1 CL2012001485A CL2012001485A CL2012001485A1 CL 2012001485 A1 CL2012001485 A1 CL 2012001485A1 CL 2012001485 A CL2012001485 A CL 2012001485A CL 2012001485 A CL2012001485 A CL 2012001485A CL 2012001485 A1 CL2012001485 A1 CL 2012001485A1
- Authority
- CL
- Chile
- Prior art keywords
- useful
- treatment
- pharmaceutical composition
- oxadol
- benzooxazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Abstract
Compuestos derivados de sulfonamida heterocíclicas; composición farmacéutica que los comprende; útiles en el tratamiento de enfermedades hiperproliferativas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3019CH2009 | 2009-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012001485A1 true CL2012001485A1 (es) | 2012-08-03 |
Family
ID=43708813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012001485A CL2012001485A1 (es) | 2009-12-08 | 2012-06-06 | Compuestos derivados de benzofurano, benzooxazol y benzo[d]oxadol, como inhibidores de mek; composicion farmaceutica que los comprende, utiles en el tratamiento de enfermedades hiperproliferativas, tales como cancer e inflamacion. |
Country Status (26)
Country | Link |
---|---|
US (1) | US8614239B2 (es) |
EP (1) | EP2509964B1 (es) |
JP (1) | JP5456908B2 (es) |
KR (1) | KR20120102750A (es) |
CN (1) | CN102648188A (es) |
AU (1) | AU2010329940B2 (es) |
BR (1) | BR112012013735A2 (es) |
CA (1) | CA2781218A1 (es) |
CL (1) | CL2012001485A1 (es) |
CO (1) | CO6551751A2 (es) |
CR (1) | CR20120311A (es) |
CU (1) | CU20120085A7 (es) |
DO (1) | DOP2012000158A (es) |
EA (1) | EA201200823A1 (es) |
EC (1) | ECSP12011984A (es) |
ES (1) | ES2484171T3 (es) |
GE (1) | GEP20135998B (es) |
GT (1) | GT201200183A (es) |
IL (1) | IL219635A0 (es) |
MA (1) | MA33848B1 (es) |
MX (1) | MX2012006561A (es) |
NI (1) | NI201200100A (es) |
PE (1) | PE20121384A1 (es) |
TN (1) | TN2012000242A1 (es) |
WO (1) | WO2011070030A1 (es) |
ZA (1) | ZA201203324B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103748085A (zh) * | 2011-06-09 | 2014-04-23 | 诺华股份有限公司 | 杂环磺酰胺衍生物 |
CA2838029A1 (en) * | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2013001372A2 (en) * | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
US9657013B2 (en) * | 2012-02-29 | 2017-05-23 | Baruch S. Blumberg Institute | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DE69710712T3 (de) | 1996-04-12 | 2010-12-23 | Warner-Lambert Co. Llc | Umkehrbare inhibitoren von tyrosin kinasen |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
EP1367057B1 (de) | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone E und F |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
DE69926536T3 (de) | 1998-12-22 | 2013-09-12 | Genentech, Inc. | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
ES2265929T3 (es) | 1999-03-30 | 2007-03-01 | Novartis Ag | Derivados de ftalazina para el tratamiento de enfermedades inflamatorias. |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
CA2545506A1 (en) * | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
JP5491199B2 (ja) * | 2007-01-19 | 2014-05-14 | アルデア バイオサイエンシズ,インコーポレイティド | Mekのインヒビター |
US20110098288A1 (en) * | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
-
2010
- 2010-12-07 GE GEAP201012745A patent/GEP20135998B/en unknown
- 2010-12-07 CA CA2781218A patent/CA2781218A1/en not_active Abandoned
- 2010-12-07 AU AU2010329940A patent/AU2010329940B2/en not_active Ceased
- 2010-12-07 WO PCT/EP2010/069099 patent/WO2011070030A1/en active Application Filing
- 2010-12-07 EP EP10790407.0A patent/EP2509964B1/en not_active Not-in-force
- 2010-12-07 MX MX2012006561A patent/MX2012006561A/es not_active Application Discontinuation
- 2010-12-07 KR KR1020127017603A patent/KR20120102750A/ko active IP Right Grant
- 2010-12-07 US US13/514,208 patent/US8614239B2/en not_active Expired - Fee Related
- 2010-12-07 EA EA201200823A patent/EA201200823A1/ru unknown
- 2010-12-07 ES ES10790407.0T patent/ES2484171T3/es active Active
- 2010-12-07 BR BR112012013735A patent/BR112012013735A2/pt not_active IP Right Cessation
- 2010-12-07 JP JP2012542525A patent/JP5456908B2/ja not_active Expired - Fee Related
- 2010-12-07 PE PE2012000778A patent/PE20121384A1/es not_active Application Discontinuation
- 2010-12-07 CN CN2010800556652A patent/CN102648188A/zh active Pending
-
2012
- 2012-05-07 ZA ZA2012/03324A patent/ZA201203324B/en unknown
- 2012-05-07 IL IL219635A patent/IL219635A0/en unknown
- 2012-05-21 TN TNP2012000242A patent/TN2012000242A1/en unknown
- 2012-05-31 CU CU2012000085A patent/CU20120085A7/es unknown
- 2012-06-06 CL CL2012001485A patent/CL2012001485A1/es unknown
- 2012-06-07 GT GT201200183A patent/GT201200183A/es unknown
- 2012-06-07 NI NI201200100A patent/NI201200100A/es unknown
- 2012-06-08 DO DO2012000158A patent/DOP2012000158A/es unknown
- 2012-06-08 CR CR20120311A patent/CR20120311A/es unknown
- 2012-06-12 CO CO12098541A patent/CO6551751A2/es not_active Application Discontinuation
- 2012-06-19 EC ECSP12011984 patent/ECSP12011984A/es unknown
- 2012-06-25 MA MA35003A patent/MA33848B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP5456908B2 (ja) | 2014-04-02 |
GT201200183A (es) | 2014-03-27 |
AU2010329940B2 (en) | 2013-05-16 |
EP2509964A1 (en) | 2012-10-17 |
NI201200100A (es) | 2012-08-13 |
WO2011070030A1 (en) | 2011-06-16 |
TN2012000242A1 (en) | 2013-12-12 |
ECSP12011984A (es) | 2012-07-31 |
ES2484171T3 (es) | 2014-08-11 |
PE20121384A1 (es) | 2012-10-13 |
CR20120311A (es) | 2012-10-04 |
ZA201203324B (en) | 2013-01-30 |
EP2509964B1 (en) | 2014-04-30 |
EA201200823A1 (ru) | 2013-02-28 |
MX2012006561A (es) | 2012-07-04 |
US20120245209A1 (en) | 2012-09-27 |
CO6551751A2 (es) | 2012-10-31 |
AU2010329940A1 (en) | 2012-05-31 |
MA33848B1 (fr) | 2012-12-03 |
GEP20135998B (en) | 2013-12-25 |
JP2013512941A (ja) | 2013-04-18 |
CN102648188A (zh) | 2012-08-22 |
BR112012013735A2 (pt) | 2019-09-24 |
CA2781218A1 (en) | 2011-06-16 |
KR20120102750A (ko) | 2012-09-18 |
DOP2012000158A (es) | 2012-09-30 |
CU20120085A7 (es) | 2012-10-15 |
IL219635A0 (en) | 2012-07-31 |
US8614239B2 (en) | 2013-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP078013A (es) | Inhibidores heterocíclicos de mek y métodos de uso de ellos | |
CL2015002565A1 (es) | Compuestos heterociclicos y sus usos relacionados | |
CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
CL2010001641A1 (es) | Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras. | |
EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
CO6362015A2 (es) | Derivados de acido 1-amino-2ciclobutiletilboronico | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
EA202090516A3 (ru) | Бициклические гетероциклы в качестве ингибиторов fgfr | |
EA201300730A1 (ru) | Производные индазолилтриазола | |
MA32508B1 (fr) | Composes organiques | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
EA201270254A1 (ru) | Производные 5-фторпиримидинона | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
EA201270257A1 (ru) | Производные n1-сульфонил-5-фторпиримидинона | |
UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
UA113541C2 (xx) | Заміщені піролідин-2-карбоксаміди | |
AR075442A1 (es) | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia | |
BR112013003671A2 (pt) | composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol | |
CL2013000263A1 (es) | Compuestos derivados de carboxamidas azaheterociclicas biciclicas (quinazolinas), como inhibidores de quinasa p70s6k; proceso de preparacion; composicion farmaceutica; kit; y su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer, inflamacion, enfermedades relacionadas con vasculogenesis. | |
EA201400771A1 (ru) | Новые производные азетидина, фармацевтические композиции и их применение | |
GT201400090A (es) | 2-tiopirimidinonas |